Payment overview · 2025
General Payments
$3,103.79
138 reported records · 23 companies
Healthcare provider profile · identity verified
Savitha Shivananda
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1104831684
Verified facts
What the public records show
CMS Open Payments records show Savitha Shivananda received $3,103.79 in general payments during 2025 across 138 reported records.
Dexcom, Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $521.31 | 16.8% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $377.42 | 12.2% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $341.64 | 11.0% | 26 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $247.19 | 8.0% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $245.77 | 7.9% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.62 | 7.4% | 14 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $181.00 | 5.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.38 | 5.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $110.69 | 3.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $109.22 | 3.5% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $103.23 | 3.3% | 5 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $79.16 | 2.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.22 | 2.0% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $60.50 | 1.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.99 | 1.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.98 | 1.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.71 | 1.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.78 | 1.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $21.65 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.82 | 0.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.87 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.79 | 0.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.85 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,035.84 | 137 |
| Education | $67.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $377.42 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $262.78 | 8 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $258.53 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $258.53 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $243.61 | 22 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $227.31 | 20 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $213.20 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $213.20 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $162.00 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $149.28 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.17 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $129.90 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $113.05 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $110.69 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $91.30 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.35 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $79.16 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $74.55 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.22 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $60.50 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $55.96 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $31.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $10.00 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 150 |
| Losartan Potassium | Losartan Potassium | 275 | 98 |
| Omeprazole | Omeprazole | 243 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 85 |
| Metformin Hcl | Metformin Hcl | 223 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 56 |
| Lisinopril | Lisinopril | 138 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 46 |
| Atenolol | Atenolol | 123 | 34 |
| Sertraline Hcl | Sertraline Hcl | 122 | 38 |
| Gabapentin | Gabapentin | 115 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 30 |
| Eliquis | Apixaban | 99 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 32 |
| Simvastatin | Simvastatin | 92 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 46 |
| Prednisone | Prednisone | 89 | 55 |
| Ozempic | Semaglutide | 78 | 18 |
| Alprazolam | Alprazolam | 77 | 23 |
| Meloxicam | Meloxicam | 74 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 29 |
| Furosemide | Furosemide | 59 | 23 |
| Celecoxib | Celecoxib | 58 | 16 |
| Montelukast Sodium | Montelukast Sodium | 58 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 56 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 18 |
| Jardiance | Empagliflozin | 55 | 21 |
| Irbesartan | Irbesartan | 54 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 30 |
| Methylprednisolone | Methylprednisolone | 45 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 16 |
| Buspirone Hcl | Buspirone Hcl | 41 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 18 |
| Famotidine | Famotidine | 40 | 19 |
| Trazodone Hcl | Trazodone Hcl | 40 | 18 |
| Azithromycin | Azithromycin | 39 | 31 |
| Tramadol Hcl | Tramadol Hcl | 39 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 21 |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 11 |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 17 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 23 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,103.79 · 138 records | Dexcom, Inc. | ABRYSVO, AIRSUPRA, APTIMA, BREZTRI, CAMZYOS, CAPLYTA, COMIRNATY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, TheraSphere Y90 Glass Microspheres 10 GBq, VOQUEZNA, VRAYLAR, VYNDAQEL, Veozah, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error